Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Swedish Orphan Biovitrum AB (OTC:BIOVF) and Sanofi SA (NASDAQ:SNY) presented results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001) in previously treated hemophilia A patients.
- The study met the primary efficacy endpoint, with once-weekly efanesoctocog alfa prophylaxis providing clinically meaningful bleed protection.
- The median and mean annualized bleeding rates (ABR) were 0.00 and 0.71, respectively.
- The study also demonstrated superior bleed protection over prior factor VIII prophylaxis with an estimated ABR reduction of 77% and a mean ABR of 0.69 compared to 2.96 on prior prophylaxis.
- Once-weekly efanesoctocog alfa showed statistically significant and clinically meaningful improvements in physical health, pain intensity, and joint health when comparing week 52 and baseline measurements.
- 96.7% of bleeds were resolved with a single 50 IU/kg dose. Efanesoctocog alfa was well tolerated, and inhibitor development to factor VIII was not detected.
- The most common treatment-emergent adverse events were headache, arthralgia, fall, and back pain.
- FDA marketing application submission occurred in June 2022, and submission in the EU will follow the availability of data from the ongoing XTEND-Kids pediatric study, expected in 2023.
- Price Action: SNY shares closed 0.12% lower at $50.16 on Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!